相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Modifiable lifestyle risk factors and C-reactive protein in patients with coronary artery disease: Implications for an anti-inflammatory treatment target population
Christopher Blaum et al.
EUROPEAN JOURNAL OF PREVENTIVE CARDIOLOGY (2021)
LDL-cholesterol lowering with evolocumab, and outcomes according to age and sex in patients in the FOURIER Trial
Peter Sever et al.
EUROPEAN JOURNAL OF PREVENTIVE CARDIOLOGY (2021)
Is the novel LDL-cholesterol goal <1.4 mmol/L achievable without a PCSK9 inhibitor in a chronic coronary population from clinical practice?
John Munkhaugen et al.
EUROPEAN JOURNAL OF PREVENTIVE CARDIOLOGY (2021)
Achievement of European guideline-recommended lipid levels post-percutaneous coronary intervention: A population-level observational cohort study
Daniel E. Harris et al.
EUROPEAN JOURNAL OF PREVENTIVE CARDIOLOGY (2021)
Impact of PCSK9 inhibitors on the quality of life of patients at high cardiovascular risk
Arturo Cesaro et al.
EUROPEAN JOURNAL OF PREVENTIVE CARDIOLOGY (2020)
2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and European Atherosclerosis Society (EAS)
Francois Mach et al.
EUROPEAN HEART JOURNAL (2020)
Application of the 2019 ESC/EAS dyslipidaemia guidelines to nationwide data of patients with a recent myocardial infarction: a simulation study
Ali Allahyari et al.
EUROPEAN HEART JOURNAL (2020)
Alirocumab in Patients With Polyvascular Disease and Recent Acute Coronary Syndrome ODYSSEY OUTCOMES Trial
J. Wouter Jukema et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2019)
Management of dyslipidaemia in patients with coronary heart disease: Results from the ESC-EORP EUROASPIRE V survey in 27 countries
Guy De Backer et al.
ATHEROSCLEROSIS (2019)
Updated Cost-effectiveness Analysis of Evolocumab in Patients With Very High-risk Atherosclerotic Cardiovascular Disease
Gregg C. Fonarow et al.
JAMA CARDIOLOGY (2019)
Statin Safety and Associated Adverse Events: A Scientific Statement From the American Heart Association
Connie B. Newman et al.
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY (2019)
2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol
Scott M. Grundy et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2019)
Simulation of the Impact of Statin Intolerance on the Need for Ezetimibe and/or Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitor for Meeting Low-Density Lipoprotein Cholesterol Goals in a Population With Atherosclerotic Cardiovascular Disease
Christopher P. Cannon et al.
AMERICAN JOURNAL OF CARDIOLOGY (2019)
2017 Update of ESC/EAS Task Force on practical clinical guidance for proprotein convertase subtilisin/kexin type 9 inhibition in patients with atherosclerotic cardiovascular disease or in familial hypercholesterolaemia
Ulf Landmesser et al.
EUROPEAN HEART JOURNAL (2018)
Adherence to Mediterranean diet, high-sensitive C-reactive protein, and severity of coronary artery disease: Contemporary data from the INTERCATH cohort
Christoph Waldeyer et al.
ATHEROSCLEROSIS (2018)
Clinical Benefit of Evolocumab by Severity and Extent of Coronary Artery Disease: Analysis From FOURIER
Marc S. Sabatine et al.
CIRCULATION (2018)
Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome
G. G. Schwartz et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel
Brian A. Ference et al.
EUROPEAN HEART JOURNAL (2017)
Atherothrombotic Risk Stratification and Ezetimibe for Secondary Prevention
Erin A. Bohula et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2017)
Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease
Marc S. Sabatine et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Simulation of Lipid-Lowering Therapy Intensification in a Population With Atherosclerotic Cardiovascular Disease
Christopher P. Cannon et al.
JAMA CARDIOLOGY (2017)
Lipid Management After First Diagnosis of Coronary Artery Disease: Contemporary Results From an Observational Cohort Study
Christoph Waldeyer et al.
CLINICAL THERAPEUTICS (2017)
Cholesterol target value attainment and lipid-lowering therapy in patients with stable or acute coronary heart disease: Results from the Dyslipidemia International Study II
Anselm K. Gitt et al.
ATHEROSCLEROSIS (2017)
Continued Statin Prescriptions After Adverse Reactions and Patient Outcomes A Cohort Study
Huabing Zhang et al.
ANNALS OF INTERNAL MEDICINE (2017)
2016 ESC/EAS Guidelines for the Management of Dyslipidaemias
Alberico L. Catapano et al.
EUROPEAN HEART JOURNAL (2016)
Interpretation of the evidence for the efficacy and safety of statin therapy
Rory Collins et al.
LANCET (2016)
Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170 000 participants in 26 randomised trials
C. Baigent et al.
LANCET (2010)
分享论文
